



Evolution, Safety, and Highly Pathogenic Influenza Viruses

Citation

Lipsitch, M., J. B. Plotkin, L. Simonsen, and B. Bloom. 2012. "Evolution, Safety, and Highly Pathogenic Influenza Viruses." *Science* 336 (6088) (June 21): 1529–1531. doi:10.1126/science.1223204.

Published Version

doi:10.1126/science.1223204

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:25124592>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



Published in final edited form as:

Science. 2012 June 22; 336(6088): 1529–1531. doi:10.1126/science.1223204.

Evolution, Safety, and Highly Pathogenic Influenza Viruses

Marc Lipsitch,

Department of Epidemiology and Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115 USA

Joshua B. Plotkin,

Department of Biology, University of Pennsylvania, Philadelphia, PA 19104 USA

Lone Simonsen, and

Department of Global Health, George Washington University School of Public Health and Health Services, Washington, DC 20037 USA

Barry Bloom

Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115 USA

Marc Lipsitch: mlipsitc@hsph.harvard.edu; Joshua B. Plotkin: jplotkin@sas.upenn.edu; Lone Simonsen: lone@gwu.edu; Barry Bloom: bbloom@hsph.harvard.edu

Abstract

Experience with influenza has shown that predictions of virus phenotype or fitness from nucleotide sequence are imperfect, and that predicting the timing and course of evolution is extremely difficult. Such uncertainty means that the risk of experiments with mammalian-transmissible, possibly highly virulent influenza viruses remains high even if some aspects of their laboratory biology are reassuring; it also implies limitations on the ability of laboratory observations to guide interpretation of surveillance of strains in the field. Given these considerations, we propose that future experiments with virulent pathogens whose accidental or deliberate release could lead to extensive spread in human populations should be limited by explicit risk-benefit considerations, in the United States and worldwide.

In response to two sets of experiments on mammalian-transmissible, modified influenza A/H5N1 viruses (1) the US Department of Health and Human Services has promulgated a new Policy on Dual Use Research of Concern (2). This policy, and other statements from US and international bodies identify the need for risk mitigation in future studies of mammalian-transmissible variants of highly pathogenic influenza virus and certain other infectious agents (3, 4), raising an important new question: how should funders, regulators and researchers evaluate what future experiments should be done with such viruses? The answer to this question depends on the relative magnitude of risks and benefits of such experiments. For influenza, useful evaluations of either risks or benefits depend in part on what we know about virus evolution. Proponents of continued research in this area suggest that knowing the mutations involved in mammalian airborne transmission will aid surveillance—allowing us to see if there is evolution in the direction of a pandemic virus. Mitigating the risk of accidental or deliberate release of these strains, as directed by the new policy (2), also depends on how well we can predict the virulence, transmissibility, and evolutionary trajectory of influenza viruses.

We contend that predictions about how particular influenza strains will behave in humans or, even more important, how they will evolve, remain highly speculative. The most striking examples of influenza's unpredictability are in the area of drug resistance. Animal models, *in vitro* studies, and mathematical models have all contributed to our understanding of drug-

resistant strains. Despite that knowledge, aspects of the spread of adamantane-resistant A/H3N2 (2003-present) and the spread of oseltamivir-resistant A/H1N1 (2007–9) took the influenza community by surprise.

Adamantanes were used to treat influenza starting in the late 1960s. Animal models showed essentially no “fitness cost” or virulence reduction attributable to mutations conferring adamantane resistance (5), which commonly emerge during treatment (6) and can spread within families (6). These observations would have predicted a high likelihood that adamantane resistance would spread widely in populations where adamantanes were used, but such spread did not occur for decades, for reasons that remain unclear. Then, in 2003–4, adamantane-resistant viruses emerged to rapidly become the dominant influenza A/H3N2 isolates globally (7, 8). While adamantane use likely played a role in the genesis and initial spread of the resistant lineage (7), the near-fixation of this lineage in global A/H3N2 isolates may have been due to the presence of immune escape mutations in the lineage (8), a selection pressure whose importance in spreading this virus could not have been confidently predicted. Also unanticipated was the persistence of resistant viruses to the present day, despite minimal use of adamantanes (8).

Resistant strains emerge de novo in several percent of influenza patients treated with the neuraminidase inhibitor oseltamivir (9). However, extensive spread of resistance was not reported before 2007. At the time, this situation was explainable by the large fitness costs observed in animal models for the most common oseltamivir-resistance mutation (10). Public health officials and virologists were therefore surprised when, in winter 2007–8, resistance to oseltamivir in A/H1N1 viruses carrying the H275Y mutation, arose and spread widely. Even more surprising was the finding that this rise was not explained by geographic patterns of antiviral use, and high prevalence of the resistant strain was first detected in Norway, where oseltamivir use was negligible (11). Only after the global spread of this drug-resistant A/H1N1 lineage have we begun to understand the additional enabling mutations (12–14) that led to its rapid emergence. While drug resistant strains were obviously anticipated under drug pressure, these experiences serve as a warning against overconfidence in predicting the timing and direction of influenza evolution.

Antigenic drift of influenza A hemagglutinin is probably the best-studied evolutionary process in any virus; yet both the timing and amino acid location of changes that lead to important antigenic changes (15) in any particular strain remain difficult to predict (16). As a result, in about half of all influenza seasons, one or more components of the trivalent vaccine is poorly matched to the circulating strains of flu (17). Predictions of virus properties from sequence information are likewise imprecise, highlighting how much more needs to be learned regarding the effects of genetic environment on properties related to individual mutations. In the 2009 pandemic, for example, the E627K mutation in the PB2 gene was expected to enhance virulence and promote transmission, but it did not spread widely, and it did not enhance virulence in animal models when introduced in the genetic background of the 2009 pandemic virus (18).

Contentions that H5N1 mutant strains might not be highly transmissible or as pathogenic as wild-type H5N1 strains in humans (19) may therefore be falsely reassuring. The evidence from ferrets that these viruses are transmissible between mammals by the airborne route, coupled with the demonstrated human virulence of wild-type avian A/H5N1 strains, close genetic precursors of the viruses created by one group (20), should be taken seriously.

By emphasizing the limits of predictability, we do not mean to suggest that molecular studies of influenza transmissibility and virulence, or surveillance of animal virus populations, lack value. Viral sequences contain important information; studying the

behavior of novel variants in the lab and adding precision to surveillance in the field are necessary if we are ever to improve our predictive powers. But because we cannot predict how these strains will behave in humans or, critically, how they will evolve, such studies on transmissible versions of dangerous zoonotic pathogens are particularly risky and deserve special treatment.

Indeed, great care was taken in the experiments now being reported (1, 20), and WHO specifically noted that the “laboratory-modified H5N1 viruses are currently stored in well-established research facilities with high security and high safety (BSL3+)” (4). However, it is not a given that all future experiments will be conducted with such care, and WHO also called it “a matter of urgency” to define “the biosafety and biosecurity conditions under which further research is conducted on the laboratory-modified H5N1 viruses” (4). In doing so, we must remember that accidents happen even under high-level containment conditions. Accidental infections of laboratory workers with SARS coronavirus (21) and with smallpox (22) and the accidental release of foot and mouth disease virus from a laboratory in the UK (23) indicate the serious and real risk of laboratory accidents, a risk that increases with the number of laboratories and workers involved. The 1977 re-emergence of the A/H1N1 influenza virus after decades of absence contributed to seasonal influenza for three decades. This virus’s genetic similarity to 1950 A/H1N1 viruses suggests it descended from a laboratory strain (24), though the exact circumstances remain unclear.

Exactly how to translate this high level of concern into the current framework of biological safety is not straightforward. US government guidelines (25) indicate the current highest level of biosafety, BSL4, “for work with dangerous and exotic agents that pose a high individual risk of life-threatening disease, which may be transmitted via the aerosol route and for which there is no available vaccine or therapy.” In practice, these guidelines are not followed literally: smallpox virus, for which there are significant vaccine stockpiles, is limited to only two BSL4 laboratories, and Ebola virus which transmits only by blood contact is classified as BSL4, whereas the SARS coronavirus, which has proven epidemic potential and no widely available vaccine, seems to meet all of the BSL4 criteria yet is handled in BSL3 laboratories. As of 2009, there were at least 14 “entities” maintaining registered BSL4 laboratories in the United States (26) at least 24 BSL4 laboratories worldwide (27), and at least 1495 BSL3 laboratories registered in the US and working with select agents (27), though the total number of BSL3 laboratories in the US is unknown (27). Comprehensive data from intramural laboratories at the National Institute of Allergy and Infectious Diseases estimate the risk of exposure as 2 per 100,000 operator-hours; only one of the twelve exposures involved in this calculation involved a clinical infection (28). Data from a larger set of US laboratories indicates 26 incidents, 8 of which resulted in documented infections, in BSL3 and BSL4 labs (not including agricultural pathogens). Another five, all involving infections, are known in non-US BSL3 and BSL4 labs, between 2002 and 2007; in the US and outside, reporting of such incidents is incomplete (28).

The modified H5N1 strains do not fit neatly into the categories established in the biosafety guidelines: aerosol transmissibility among humans is possible (and is a key reason for interest in their study) but unproven; vaccines may protect laboratory workers, but are not available on a scale sufficient for the general population, which might be at risk if a laboratory worker were infected and were able to transmit the infection to others. While we are not in a position to resolve the debate about the proper biosafety level, we do believe that funding agencies and regulators should limit the number of laboratories and individuals working on these modified strains. Each additional laboratory and individual worker adds to the risk of accidental or malicious release, and so there should be a strong presumption against increasing these numbers unless the benefits of an additional study are very well justified scientifically. Biological safety depends not only on the physical barriers of BSL3

or BSL4 facilities, but importantly on the experience, training and skill of laboratory workers; these factors should also be considered when deciding on who is permitted to work with these agents. At present, US law requires specific safety and security measures for work on Select Agents (including certain highly pathogenic influenza viruses). Principles for biosafety are laid out in the widely-used *Biosafety in Microbiological and Biomedical Laboratories* (25). We recommend that compliance with these measures and principles be actively monitored by CDC, on a basis more frequent than the current requirement for federal inspection of BSL-3 labs every three years and when a new select agent is added (27, 29). These requirements apply only within the United States; we share the concern expressed by many experts about variation in biosafety practices worldwide (27). For experiments on the evolution of viral or bacterial transmissibility to mammals, there should be an explicit requirement to justify why the research must be done with virulent strains.

Traditional peer-reviewed funding decisions evaluate scientific merit first, and then undertake risk mitigation if it is considered necessary; the DURC policy in the US (2) does not specify how, if at all, this approach would change. We propose that the decision about whether research on mammalian-transmissible H5N1 viruses or agents with similar potential for damage to public health should be funded or should proceed with restrictions should not be left to each department or agency, as some agencies may lack the relevant expertise to evaluate risks and benefits in light of the overall portfolio of studies already approved or underway. A single committee, responsible to multiple departments within the government and including outside experts, for example in evolutionary microbiology and biodefense as well as virology, needs to review the small number of proposals identified by grant administrators or scientific review committees that involve pathogens whose accidental or deliberate release would represent a major threat to public health. In contrast to the NSABB, which is only advisory, this committee should have decision-making authority. Similar considerations should motivate policies outside the United States (27).

Each additional study of mammalian-transmissible, highly pathogenic influenza will improve our understanding and may move us closer to an ability to control such viruses, but will also increase the risk of an accident that could trigger a global public health disaster, especially if evolution proceeds in an unfavorable direction. This exceptional level of risk should motivate exceptional caution by scientists, funders and regulators worldwide.

Acknowledgments

We thank David Franz, Frederick Hayden, Richard Malley and Bruce Levin for helpful comments.

References

1. Imai M, et al. *Nature*. 2012 in press.
2. US Government. [accessed May 14, 2012] United States Government Policy for Oversight of Life Sciences Dual Use Research of Concern. 2012. http://oba.od.nih.gov/oba/biosecurity/PDF/United_States_Government_Policy_for_Oversight_of_DURC_FINAL_version_032812.pdf
3. US National Science Advisory Board for Biosafety. [accessed May 9, 2012] National Science Advisory Board for Biosecurity Findings and Recommendations March 29–30, 2012. 2012. http://oba.od.nih.gov/oba/biosecurity/PDF/03302012_NSABB_Recommendations.pdf
4. World Health Organization. [accessed May 9, 2012] Report on technical consultation on H5N1 research issues. 2012. http://www.who.int/entity/influenza/human_animal_interface/mtg_report_h5n1.pdf
5. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. *J Infect Dis*. Nov.1991 164:969. [PubMed: 1940477]
6. Hayden FG, et al. *N Engl J Med*. Dec 21.1989 321:1696. [PubMed: 2687687]

7. Bright RA, et al. *Lancet*. Oct 1.2005 366:1175. [PubMed: 16198766]
8. Simonsen L, et al. *Mol Biol Evol*. Aug.2007 24:1811. [PubMed: 17522084]
9. Kiso M, et al. *Lancet*. Aug-Sep;2004 364:759. [PubMed: 15337401]
10. Herlocher ML, et al. *J Infect Dis*. Nov 1.2004 190:1627. [PubMed: 15478068]
11. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. *Euro Surveill*. Feb 5.2009 :14.
12. Bloom JD, Gong LI, Baltimore D. *Science*. Jun 4.2010 328:1272. [PubMed: 20522774]
13. Kryazhimskiy S, Dushoff J, Bazykin GA, Plotkin JB. *PLoS genetics*. Feb.2011 7:e1001301. [PubMed: 21390205]
14. Bouvier NM, Rahmat S, Pica N. *Journal of virology*. Apr 24.2012
15. Plotkin JB, Dushoff J. *Proc Natl Acad Sci U S A*. Jun 10.2003 100:7152. [PubMed: 12748378]
16. Koelle K, Cobey S, Grenfell B, Pascual M. *Science*. Dec 22.2006 314:1898. [PubMed: 17185596]
17. Carrat F, Flahault A. *Vaccine*. Sep 28.2007 25:6852. [PubMed: 17719149]
18. Herfst S, et al. *J Virol*. Apr.2010 84:3752. [PubMed: 20130063]
19. Cohen J. *Science*. Mar 9.2012 335:1155. [PubMed: 22403358]
20. Herfst S, Osterhaus AD, Fouchier RA. *J Infect Dis*. Jun.2012 205:1628. [PubMed: 22454474]
21. *Euro Surveill*. 2003;7. pii=2347.
22. Pennington H. *Bulletin of the World Health Organization*. 2003; 81:762. [PubMed: 14758439]
23. UK Health and Safety Executive. Final report on potential breaches to biosecurity at the Pirbright site. London, UK: 2007. <http://www.hse.gov.uk/news/2007/footandmouth.htm>
24. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. *Microbiological reviews*. Mar. 1992 56:152. [PubMed: 1579108]
25. US Department of Health and Human Services. HHS publication no (CDC) 21–1112. 5. 2009. Biosafety in Microbiological and Biomedical Laboratories.
26. US Government Accountability Office. High-containment laboratories: National strategy for oversight is needed. Document GAO-09-574. 2009.
27. Hottes, AK.; Rusek, B.; Sharples, F. National Academy of Sciences and National Research Council. *Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories*. National Academies Press; Washington, DC: 2012. Committee on Anticipating Biosecurity Challenges of the Global Expansion of High Containment Biological Laboratories.
28. US Department of Homeland Security. [accessed May 13, 2012] National Bio and Agro-defense Facility Final Environmental Impact Statement, Appendix B. 2008. http://www.dhs.gov/xlibrary/assets/nbaf_feis_appendix_b.pdf
29. US Government. [accessed May 19, 2012] 42 CFR 73 <http://www.selectagents.gov/resources/42CFR73.pdf>